Texas HB2412 requires health benefit plans to cover glucagon-like peptide-1 receptor agonists for obesity treatment.

HB2412 mandates that health benefit plans offering prescription drug benefits must cover glucagon-like peptide-1 receptor agonists to treat obesity. This applies to various types of health benefit plans, including those under the state Medicaid program. The provisions of this Act take effect on September 1, 2025, and apply to plans delivered, issued for delivery, or renewed on or after January 1, 2026. If a waiver or authorization from a federal agency is necessary for implementation, the affected state agency may delay implementation until the waiver or authorization is granted.

Texas HB2412 requires health benefit plans to cover glucagon-like peptide-1 receptor agonists for obesity treatment.

HB2412 mandates that health benefit plans offering prescription drug benefits must cover glucagon-like peptide-1 receptor agonists to treat obesity. This applies to various types of health benefit plans, including those under the state Medicaid program. The provisions of this Act take effect on September 1, 2025, and apply to plans delivered, issued for delivery, or renewed on or after January 1, 2026. If a waiver or authorization from a federal agency is necessary for implementation, the affected state agency may delay implementation until the waiver or authorization is granted.